By Dr. Lei Deng University of Washington & Fred Hutch Watch Dr. Lei Deng’s overview of the KEYNOTE-671
MoreBy Dr. Lei Deng University of Washington & Fred Hutch Watch Dr. Lei Deng’s overview of the KEYNOTE-671 and NADIM II trials, with important implications for
Show moreDr. Talha Badar of Mayo Clinic discusses the results of Quantum First, a randomized, phase III trial evaluating the efficacy of Quizartinib in treating Acute Myeloid Leukemia (AML) with FLT3-ITD
Show moreDr. Richa Parikh interviewed Dr. Shaji Kumar of Mayo Clinic about his recommendations for the treatment of myeloma.
Show moreDr. Dipesh Uprety interviewed Dr. Chadi Nabhan about his new book, Toxic Exposure. Watch the video to hear more about the book and Dr. Nabhan’s involvement in three court cases
Show moreDr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab
Show moreDr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase III study of sorafenib versus stereotactic body radiation
Show more